OncoMatch/Clinical Trials/NCT06005740
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
Is NCT06005740 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TORL-4-500 for advanced solid tumor.
Treatment: TORL-4-500 — This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
Advanced solid tumor; Measurable disease, per RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapeutic, investigational, or other therapies for the treatment of cancer
Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-4-500
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Phoenix · Phoenix, Arizona
- Providence Medical Foundation · Fullerton, California
- UCLA - JCCC Clinical Research Unit · Los Angeles, California
- Torrance Memorial Physician Network · Torrance, California
- Mayo Clinic Jacksonville · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify